Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment

Endocrine-Related Cancer

Volumn 18, Issue 5, 2011, Pages 565-577

  Drury, S C ^a,b   Detre, S ^b   Leary, A ^c   Salter, J ^a,b   Reis Filho, J ^a   Barbashina, V ^a   Marchio, C ^d   Lopez Knowles, E ^a   Ghazoui, Z ^a   Habben, K ^e   Arbogast, S ^e   Johnston, S ^b   Dowsett, M ^a,b  

^a Breakthrough Breast Cancer Research Centre   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITY OF TURIN   (Italy)

^e ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; SOMATOMEDIN C RECEPTOR; STATHMIN; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; PIK3CA GENE; PRIMARY TUMOR; PROTEIN EXPRESSION; RECURRENT CANCER;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; RECEPTOR, IGF TYPE 1; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; STATHMIN; TAMOXIFEN; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054921787     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-10-0046     Document Type: Article

References (40)

1. Alli E, Bash-Babula J, Yang JM & Hait WN 2002 Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Research 62 6864-6869. (Pubitemid 35424074)
2. Alli E, Yang JM & Hait WN 2007 Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 26 1003-1012. (doi:10.1038/sj.onc.1209864)
3. Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME et al. 2000 Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Research 60 2155-2162. (Pubitemid 30225178)
4. Brattsand G 2000 Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. British Journal of Cancer 83 311-318. (doi:10.1054/bjoc.2000.1264)
5. Bunone G, Briand PA, Miksicek RJ & Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal 15 2174-2183. (Pubitemid 26141134)
6. Chan TW, Pollak M & Huynh H 2001 Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 1 82 780. Clinical Cancer Research 7 2545-2554. (Pubitemid 32751661)
7. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB & Lee AV 2003 Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Molecular Endocrinology 17 575-588. (doi:10.1210/me.2002-0318)
8. Curmi PA, Nogués C, Lachkar S, Carelle N, Gonthier MP, Sobel A, Lidereau R & Biéche I 2000 Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. British Journal of Cancer 82 142-150. (doi:10.1054/bjoc.1999.0891)
9. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K & Howell A 2007 Long-term results of tamoxifen prophylaxis for breast cancer -96-month follow-up of the randomized IBIS-I trial. Journal of National Cancer Institute 99 272-282. (doi:10.1093/jnci/djk049)
10. Detre S, SaclaniJotti G & Dowsett M 1995 A quickscore method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. Journal of Clinical Pathology 48 876-878. (doi:10.1136/jcp.48.9.876)
11. Dowsett M 2006 Estrogen receptor: methodology matters. Journal of Clinical Oncology 24 5626-5628. (doi:10.1200/JCO.2006.08.3485)
12. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E et al. 2008 Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. Journal of Clinical Oncology 26 1059-1065. (doi:10.1200/JCO.2007.12.9437)
13. Dupont J & Le Roith D 2001 Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Molecular Pathology 54 149-154. (doi:10.1136/mp.54.3.149)
14. Early Breast Cancer Trialists' Collaborative Group 1988 Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28 896 women. New England Journal of Medicine 319 1681-1692. (doi:10.1056/NEJM198812293192601)
15. Early Breast Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 1451-1467. (doi:10.1016/S0140-6736(97)11423-4)
16. Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL & Lykkesfeldt AE 2005 Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocrine-Related Cancer 12 599-614. (doi:10.1677/erc.1.00946)
17. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M & Nicholson RI 2005 Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocrine-Related Cancer 12 (Suppl 1) S99-S111. (doi:10.1677/erc.1. 01005)
18. Golouh R, Cufer T, Sadikov A, Nussdorfer P, Usher PA, Brünner N, Schmitt M, Lesche R, Maier S, Timmermans M et al. 2008 The prognostic value of stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. Breast Cancer Research and Treatment 110 317-326. (doi:10.1007/s10549- 007-9724-3)
19. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK & Dowsett M 2005 Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. Journal of Clinical Oncology 23 2469-2476. (doi:10.1200/JCO.2005.01.172)
20. Guvakova MA & Surmacz E 1997 Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Research 57 2606-2610. (Pubitemid 27283767)
21. Howell A, Harland RN, Barnes DM, Baildam AD, Wilkinson MJS, Hayward E, Swindell R & Sellwood RA 1987 Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Research 47 300-304. (Pubitemid 17002140)
22. Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE & Nicholson RI 2003 Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81 81-93. (doi:10.1023/A:1025484908380)
23. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR & Dowsett M 1995 Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Research 55 3331-3338.
24. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W et al. 2009 PIK3CA mutation associates with improved outcome in breast cancer. Clinical Cancer Research 15 5049-5059. (doi:10.1158/1078-0432.CCR-09-0632)
25. Knowlden JM, Hutcheson IR, Barrow D, Gee JMW & Nicholson RI 2005 Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 146 4609-4618. (doi:10.1210/en.2005-0247)
26. Law JH, Habibi G, Hu K, Masoudi H, Wang MYC, Stratford AL, Park E, Gee JMW, Finlay P, Jones HE et al. 2008 Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Research 68 10238-10246. (doi:10.1158/0008- 5472.CAN-08-2755)
27. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M & Schiff R 2008 Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Research 68 826-833. (doi:10.1158/0008-5472. CAN-07-2707)
28. Miller TW, Perez-Torres M, Narasanna A, Guix M, Stâl O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP et al. 2009 Loss of phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Research 69 4192-4201. (doi:10.1158/0008-5472.CAN-09-0042)
29. Nicholson RI, Hutcheson IR, Britton D, Knowlden JM, Jones HE, Harper ME, Hiscox SE, Barrow D & Gee JM 2005 Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. Journal of Steroid Biochemistry and Molecular Biology 93 257-262. (doi:10.1016/j.jsbmb.2004.12.006)
30. Pancholi S, Lykkesfeldt AE, Hilmi C, Banerjee S, Leary A, Drury S, Johnston S, Dowsett M & Martin LA 2008 ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocrine-Related Cancer 15 985-1002. (doi:10.1677/ERC-07-0240)
31. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID & Pezzino V 1993 Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Research 53 3736-3740. (Pubitemid 23252035)
32. Pekonen F, Partanen S, Mäkinen T & Rutanen EM 1988 Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Research 48 1343-1347. (Pubitemid 18075556)
33. Peyrat JP, Bonneterre J, Beuscart R, Djiane J & Demaille A 1988 Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Research 48 6429-6433.
34. Quinn E, Salter J & Hills M 2008 Concordance between tissue microarray and whole tissue sections for ER expression and PgR and HER-2 Status: a pilot study for the Trans-ATAC trial. European Journal of Cancer 140 (Suppl 6) abstract 311.
35. Riedemann J & Macaulay VM 2006 IGF1R signalling and its inhibition. Endocrine-Related Cancer 13 (Suppl 1) S33-S43. (doi:10.1677/erc.1.01280)
36. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J et al. 2005 PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Research 65 2554-2559. (doi:10.1158/0008-5472-CAN-04-3913)
37. Saal LH, Johansson P, olm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L et al. 2007 Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. PNAS 104 7564-7569. (doi:10.1073/pnas.0702507104)
38. Sakr RA, Barbashina V, Morrogh M, Chandarlapaty S, Andrade VP, Arroyo CD, Olvera N & King TA 2010 Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Applied Immunohistochemistry & Molecular Morphology 18 371-374. (doi:10.1097/PAI.0b013e3181d50bd5)
39. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A et al. 2008 An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Research 68 6084-6091. (doi:10.1158/0008-5472.CAN-07-6854)
40. Stewart AJ, Johnson MD, May FE & Westley BR 1990 Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. Journal of Biological Chemistry 265 21172-21178. (Pubitemid 120014136)